bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S5 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Authors: McClements Lana , Yakkundi Anita , Papaspyropoulos Angelos , Harrison Hannah , Ablett Matthew P. , Jithesh Puthen V. , McKeen Hayley D. , Bennett Rachel , Donley Christopher , Kissenpfennig Adrien , McIntosh Stuart , McCarthy Helen O. , O'Neill Eric , Clarke Robert B. , Robson Tracy
Published: April 2023

Figure S5 - PDF file 48K, Figure S5. High FKBPL and low Nanog expression correlates with better DMFS and shows a trend towards better RFS. Samples with opposing FKBPL and Nanog expression (high FKBPL/low Nanog and low FKBPL/high Nanog) were analysed using microarray data from publically available data set (GSE7390). Samples were stratified based on median expression values of NANOG and FKBPL. Kaplan-Meier survival curves of breast cancer patients (n=94) presented
Figure S4 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Authors: McClements Lana , Yakkundi Anita , Papaspyropoulos Angelos , Harrison Hannah , Ablett Matthew P. , Jithesh Puthen V. , McKeen Hayley D. , Bennett Rachel , Donley Christopher , Kissenpfennig Adrien , McIntosh Stuart , McCarthy Helen O. , O'Neill Eric , Clarke Robert B. , Robson Tracy
Published: April 2023

Figure S4 - PDF file 73K, Figure S4. (A) Protein levels of Nanog and Oct4 in MDA-231 cells following treatment with HA or AD-01, alone or in combination. (B) Protein levels of Nanog and Oct4 in MDA-231 cells following transfection with FKBPL siRNA (siFKBPL) or NT siRNA (siNT) evaluated by immunofluorescence
Supplementary Figure 5 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Authors: Zhao Qi , Caballero Otavia L. , Davis Ian D. , Jonasch Eric , Tamboli Pheroze , Yung W.K. Alfred , Weinstein John N. , Strausberg Robert L. , Yao Jun
Published: April 2023

PDF file - 497K, Gene copy number profiles of individual FGFR2-IIIb-1/2 RCCs and FGFR2-IIIc ccRCCs
Supplementary Table and Figures from Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
Authors: Renshaw Jane , Taylor Kathryn R. , Bishop Ryan , Valenti Melanie , De Haven Brandon Alexis , Gowan Sharon , Eccles Suzanne A. , Ruddle Ruth R. , Johnson Louise D. , Raynaud Florence I. , Selfe Joanna L. , Thway Khin , Pietsch Torsten , Pearson Andrew D. , Shipley Janet
Published: April 2023

Supplementary Table and Figures - PDF file 184K, Suppl Table S1: Immunohistochemical analysis indicates correlation between pAKT(Ser473),pERK1/2(Thr202/Tyr204) and pS6(Ser235/236) in primary tumours Fig S1. High level expression of p110delta in two of four ARMS cell lines. Fig S2. PIK3CA KD does not induce cell cycle arrest or apoptosis in the growth inhibited RMS cells. Fig S3. Downregulation of PTEN expression appears to be associated with delayed inhibition of AKT phosphorylation in RH30 cells following p110� KD. Fig S4 Increased sensitivity of the RMS-1 PIK3CA KD line to TGX221, and of the RMS-1, RD and RMS-YM KD lines to ZSTK474. Fig S5 Equivalent changes in the biomarkers of MAPK and PI3K activity at 6h in vivo, to those seen in vitro following acute dosing with AZD6244 and AZD8055 alone, and in combination, with recovery to control levels correlating with plasma and tumor clearance of both drugs. Fig S6 Tolerability study of twice daily dosing of 10mk/kg po AZD6244 and AZD8055 indicates reversible weight loss with combination treatment, while PK analysis of tail vein blood spots confirms drug-drug interactions. Fig S7 Dose-finding therapeutic study defines a once daily treatment schedule of AZD6244, 10mg/kg p.o., and AZD8055, 20mg/kg p.o., as well tolerated and active when given in combination
Supplementary Table 1 from Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Authors: Liang Ji , Piao Yuji , Holmes Lindsay , Fuller Gregory N. , Henry Verlene , Tiao Ningyi , de Groot John F.
Published: April 2023

PDF file 42K, MPO expression correlates with glioblastoma grades
Supplementary Table S5 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

Composition and mapping of the gene modules.
Supplementary igure 1 from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor
Authors: Tomita Yusuke , Yuno Akira , Tsukamoto Hirotake , Senju Satoru , Kuroda Yasuhiro , Hirayama Masatoshi , Irie Atsushi , Kawahara Kenta , Yatsuda Junji , Hamada Akinobu , Jono Hirofumi , Yoshida Koji , Tsunoda Takuya , Kohrogi Hirotsugu , Yoshitake Yoshihiro , Nakamura Yusuke , Shinohara Masanori , Nishimura Yasuharu
Published: April 2023

Supplementary Figure 1 - PDF file 188K, KIF20A-derived and promiscuous HLA class II-binding peptides predicted by a recently developed computer algorithm
Supplementary Table 2 from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor
Authors: Tomita Yusuke , Yuno Akira , Tsukamoto Hirotake , Senju Satoru , Kuroda Yasuhiro , Hirayama Masatoshi , Irie Atsushi , Kawahara Kenta , Yatsuda Junji , Hamada Akinobu , Jono Hirofumi , Yoshida Koji , Tsunoda Takuya , Kohrogi Hirotsugu , Yoshitake Yoshihiro , Nakamura Yusuke , Shinohara Masanori , Nishimura Yasuharu
Published: April 2023

Supplementary Table 2 - PDF file 24K, HLA-A, -DR and -DP genotypes of healthy donors
Supplementary Figure 1 from PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival
Authors: Rogers Hazel A. , Mayne Cerys , Chapman Rebecca J. , Kilday John-Paul , Coyle Beth , Grundy Richard G.
Published: April 2023

PDF file - 163K, Survival analysis of P-AKT in tumors from patients in two clinical trial cohorts, CNS9204 and CNS9904,using the Kaplan Meier method with a log rank test. For the CNS9204 trial a significant association was found between P-AKT-N positivity and a worse PFS (p=0.04). An association with a worse PFS just below significance was found for P-AKT in both trial cohorts and P-AKT-N in the CNS9904 cohort.
Supplementary Table 3 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
Authors: Yin Xuefeng , Luistro Leopoldo , Zhong Hua , Smith Melissa , Nevins Tom , Schostack Kathleen , Hilton Holly , Lin Tai-An , Truitt Theresa , Biondi Denise , Wang Xiaoqian , Packman Kathryn , Rosinski Jim , Berkofsky-Fessler Windy , Tang Jian-Ping , Pant Saumya , Geho David , Vega-Harring Suzana , DeMario Mark , Levitsky Hy , Simcox Mary
Published: April 2023

XLS file, 193K, Sorted Affymetrix gene array data.
Supplementary Figure 3 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
Authors: Yin Xuefeng , Luistro Leopoldo , Zhong Hua , Smith Melissa , Nevins Tom , Schostack Kathleen , Hilton Holly , Lin Tai-An , Truitt Theresa , Biondi Denise , Wang Xiaoqian , Packman Kathryn , Rosinski Jim , Berkofsky-Fessler Windy , Tang Jian-Ping , Pant Saumya , Geho David , Vega-Harring Suzana , DeMario Mark , Levitsky Hy , Simcox Mary
Published: April 2023

PDF file, 771K, TWEAK promotes proliferation and survival signaling with minimal effect on cell viability.
Supplementary Tables 1, 3 and 4 from BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
Authors: Mar Victoria J. , Wong Stephen Q. , Li Jason , Scolyer Richard A. , McLean Catriona , Papenfuss Anthony T. , Tothill Richard W. , Kakavand Hojabr , Mann Graham J. , Thompson John F. , Behren Andreas , Cebon Jonathan S. , Wolfe Rory , Kelly John W. , Dobrovic Alexander , McArthur Grant A.
Published: April 2023

Supplementary tables 1, 3 and 4 - XLSX file 31K, 1. Performance summary of exome sequencing and capture kit used for each sample 3. List of genes for each melanoma subtype 4. List of potential actionable mutations in BRAF/NRAS wild-type tumors
Supplementary Figure 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Tabernero Josep , Markman Ben , Patnaik Amita , Tolcher Anthony W. , Baselga José , Shi Weiliang , Egile Coumaran , Ruiz-Soto Rodrigo , Laird A. Douglas , Miles Dale , LoRusso Patricia M.
Published: April 2023

PDF file - 490KB, Supplementary Figure 2. Effects of SAR245409 on Plasma Fasting Insulin and Fasting Glucose.
Supplementary Figure Legend from BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
Authors: Mar Victoria J. , Wong Stephen Q. , Li Jason , Scolyer Richard A. , McLean Catriona , Papenfuss Anthony T. , Tothill Richard W. , Kakavand Hojabr , Mann Graham J. , Thompson John F. , Behren Andreas , Cebon Jonathan S. , Wolfe Rory , Kelly John W. , Dobrovic Alexander , McArthur Grant A.
Published: April 2023

Supplementary Figure Legend - PDF file 57K, Supplementary figure legend.
Supplementary Tables 3 - 7 from RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Rampias T. , Giagini A. , Siolos S. , Matsuzaki H. , Sasaki C. , Scorilas A. , Psyrri A.
Published: April 2023

PDF file - 134KB, Regression analysis examining the relationship between time to progression and HRAS mutation.
CCR Translation for This Article from Telomere Content and Risk of Second Malignant Neoplasm in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Authors: Gramatges Maria M. , Liu Qi , Yasui Yutaka , Okcu M. Fatih , Neglia Joseph P. , Strong Louise C. , Armstrong Gregory T. , Robison Leslie L. , Bhatia Smita
Published: April 2023

CCR Translation for This Article from Telomere Content and Risk of Second Malignant Neoplasm in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Supplementary Figure 6 from RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Rampias T. , Giagini A. , Siolos S. , Matsuzaki H. , Sasaki C. , Scorilas A. , Psyrri A.
Published: April 2023

PDF file - 138KB, MEK inhibition and cetuximab sensitivity.
Supplementary Figure 5 from RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Rampias T. , Giagini A. , Siolos S. , Matsuzaki H. , Sasaki C. , Scorilas A. , Psyrri A.
Published: April 2023

PDF file - 122KB, qRT-PCR primers validation.
Supplementary Figure 3 from RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Rampias T. , Giagini A. , Siolos S. , Matsuzaki H. , Sasaki C. , Scorilas A. , Psyrri A.
Published: April 2023

PDF file - 125KB, qRT-PCR analysis.
Supplementary Figure 1 from RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Rampias T. , Giagini A. , Siolos S. , Matsuzaki H. , Sasaki C. , Scorilas A. , Psyrri A.
Published: April 2023

PDF file - 149KB, Cetuximab growth response of head and neck cancer cell lines.
Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Authors: Jain Nitin , Curran Emily , Iyengar Neil M. , Diaz-Flores Ernesto , Kunnavakkam Rangesh , Popplewell Leslie , Kirschbaum Mark H. , Karrison Theodore , Erba Harry P. , Green Margaret , Poire Xavier , Koval Greg , Shannon Kevin , Reddy Poluru L. , Joseph Loren , Atallah Ehab L. , Dy Philip , Thomas Sachdev P. , Smith Scott E. , Doyle L. Austin , Stadler Walter M. , Larson Richard A. , Stock Wendy , Odenike Olatoyosi
Published: April 2023

PDF file - 50K, Primers for KIT gene mutation testing.
Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Authors: Baker Sharyn D. , Zimmerman Eric I. , Wang Yong-Dong , Orwick Shelley , Zatechka Douglas S. , Buaboonnam Jassada , Neale Geoffrey A. , Olsen Scott R. , Enemark Eric J. , Shurtleff Sheila , Rubnitz Jeffrey E. , Mullighan Charles G. , Inaba Hiroto
Published: April 2023

PDF file, 25K, Sorafenib and sorafenib N-oxide plasma concentrations.
Supplementary Figure Legends from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Authors: Baker Sharyn D. , Zimmerman Eric I. , Wang Yong-Dong , Orwick Shelley , Zatechka Douglas S. , Buaboonnam Jassada , Neale Geoffrey A. , Olsen Scott R. , Enemark Eric J. , Shurtleff Sheila , Rubnitz Jeffrey E. , Mullighan Charles G. , Inaba Hiroto
Published: April 2023

PDF file, 53K.
Supplementary Figure 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Authors: Baker Sharyn D. , Zimmerman Eric I. , Wang Yong-Dong , Orwick Shelley , Zatechka Douglas S. , Buaboonnam Jassada , Neale Geoffrey A. , Olsen Scott R. , Enemark Eric J. , Shurtleff Sheila , Rubnitz Jeffrey E. , Mullighan Charles G. , Inaba Hiroto
Published: April 2023

PDF file, 242K, FLT3 tyrosine kinase domain mutations induce IL3-independent Ba/F3 cell transformation and show varying sensitivity to Quizartinib and Midostaurin.
Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Authors: Baker Sharyn D. , Zimmerman Eric I. , Wang Yong-Dong , Orwick Shelley , Zatechka Douglas S. , Buaboonnam Jassada , Neale Geoffrey A. , Olsen Scott R. , Enemark Eric J. , Shurtleff Sheila , Rubnitz Jeffrey E. , Mullighan Charles G. , Inaba Hiroto
Published: April 2023

PDF file, 76K, Identification of FLT3 tyrosine kinase domain mutations.
Supplementary Methods, Figures 1 - 7 from Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Authors: Guinney Justin , Ferté Charles , Dry Jonathan , McEwen Robert , Manceau Gilles , Kao KJ , Chang Kai-Ming , Bendtsen Claus , Hudson Kevin , Huang Erich , Dougherty Brian , Ducreux Michel , Soria Jean-Charles , Friend Stephen , Derry Jonathan , Laurent-Puig Pierre
Published: April 2023

PDF file - 219K, Supplemental Figure 1. A We evaluated 4 "RAS" signatures across 4 CRC data sets to assess their ability to discriminate KRAS mutant samples from KRAS wild-type. Supplemental Figure 2. The lower observed RIS of KRAS codon 13 mutated samples relative to KRAS codon 12 mutated samples may be a result of the imbalanced distribution of these mutations in the training data. Supplemental Figure 3. RIS distribution by mutation of KRAS, BRAF, NRAS mutations, and wild-type. Supplemental Figure 4. RAS index score (RIS) for PIK3CA mutant samples by exon in the TCGA CRC cohort. Supplemental Figure 5. Distribution of RIS for the subset of colorectal samples (n=19) within the Cancer Cell Line Encylopedia (CCLE), separated by KRAS codon, BRAF V600E, PIK3CA (KRAS/BRAF wild-type), or wild-type (no KRAS/BRAF/PIK3CA) mutation. Supplemental Figure 6. In the mouse early passage cohort (n=26), our RAS model outperforms the KRAS/BRAF mutation model (p=0.06 vs p > .1, respectively). Supplemental Figure 7. Association of RIS and cetuximab response for metastatic colorectal patients (Khambata-Ford, et al.) Patients annotated according to treatment response: Progressive Disease (PD), Stable Disease (SD) and Partial Response (PR) as well as KRAS mutation status.
Supplementary Figure 6 from Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
Authors: Wu Chao-Yi , Yang Li-Hua , Yang Huang-Yu , Knoff Jayne , Peng Shiwen , Lin Yi-Hsin , Wang Chenguang , Alvarez Ronald D. , Pai Sara I. , Roden Richard B.S. , Hung Chien-Fu , Wu T-C
Published: April 2023

PDF file - 1656K, Characterization of the distribution of CD11b+ myeloid cells and CD11b+ Gr-1+ MDSCs in tumor, spleen and DLN after radiation.
Legend Supplementary Figure 1 from EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma
Authors: Behrens Carmen , Solis Luisa M. , Lin Heather , Yuan Ping , Tang Ximing , Kadara Humam , Riquelme Erick , Galindo Hector , Moran Cesar A. , Kalhor Neda , Swisher Stephen G. , Simon George R. , Stewart David J. , Lee J. Jack , Wistuba Ignacio I.
Published: April 2023

PDF file 55K, Legend Supplementary Figure 1
Supplementary Figure 3 from The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors
Authors: Juliachs M. , Muñoz C. , Moutinho C.A. , Vidal A. , Condom E. , Esteller M. , Graupera M. , Casanovas O. , Germà J.R. , Villanueva A. , Viñals F.
Published: April 2023

PDF file - 270K, In Figure S3 we demonstrate how the sensitivity of GCT27 cells to CDDP is lineally proportional to activated AKT expression levels.
Supplementary Figure 2 from Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
Authors: Leshchenko Violetta V. , Kuo Pei-Yu , Jiang Zewei , Thirukonda Venu K. , Parekh Samir
Published: April 2023

PDF file - 887K, DAC induces expression of aberrantly methylated and expressed genes in TMZ resistant DLBCL.
Supplementary Figure 4 from Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells
Authors: Guillerme Jean-Baptiste , Boisgerault Nicolas , Roulois David , Ménager Jérémie , Combredet Chantal , Tangy Frédéric , Fonteneau Jean-François , Gregoire Marc
Published: April 2023

PDF file - 223K, Supplemental Figure 4: Activation of pDC in response to MV-infected tumor cells is independent of MV replication in pDC and infection by CD46. (A) pDC were cultured with IL-3 alone, R848, IL-3/MV-eGFP (MV), IL-3/MV-eGFP with 10mg/ml of anti-CD46 or IL-3/UV-irradiated MV-eGFP (MV*) at MOI=1 during 18hrs. Expression of CD83, CD80 and CD86 by pDC was determined by flow cytometry. (B) pDC were cultured with IL-3, UV-irradiated M18, MV-infected M18 (M18MV) in presence or absence of 10mg/ml of anti-CD46 (Hycult biotech), or MV-infected M18 irradiated by UV before exposition to pDC (M18MV*). Expression of CD83, CD80 and CD86 by pDC (gate on BDCA-4+/HLA-DR+ cells) was determined by flow cytometry. (C) IFN-a production by pDC measured by ELISA. (D) MV-eGFP infection inhibition of M18 by 10mg/ml of anti-CD46 monoclonal antibody after 72hrs of culture.
Supplementary Table 2 from Association of RASSF1A and p63 with Poor Recurrence-Free Survival in Node-Negative Stage I–II Non–Small Cell Lung Cancer
Authors: Ko Eunkyung , Lee Bo Bin , Kim Yujin , Lee Eun Ju , Cho Eun Yoon , Han Jungho , Shim Young Mog , Park Joobae , Kim Duk-Hwan
Published: April 2023

PDF file - 58 KB, Association of T stage with recurrence (N=328)
Supplementary Figure Legends from The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Authors: Czystowska Malgorzata , Gooding William , Szczepanski Miroslaw J. , Lopez-Abaitero Andres , Ferris Robert L. , Johnson Jonas T. , Whiteside Theresa L.
Published: April 2023

PDF file - 68 KB
Figure S7 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Authors: Liu Tao , Hu Wei , Dalton Heather J. , Choi Hyun Jin , Huang Jie , Kang Yu , Pradeep Sunila , Miyake Takahito , Song Jian H. , Wen Yunfei , Lu Chunhua , Pecot Chad V. , Bottsford-Miller Justin , Zand Behrouz , Jennings Nicholas B. , Ivan Cristina , Gallick Gary E. , Baggerly Keith A. , Hangauer David G. , Coleman Robert L. , Frumovitz Michael , Sood Anil K.
Published: April 2023

PDF file 86K, Figure S7. (A) Western blot results showing PTEN expression in RMUG-S and RMUG-L cells. PTEN expression is null in the RMUG-L cells. (B) MTT assay results showing cytotoxicity of an Akt1/2 inhibitor in RMUG-S and RMUG-L cells exposed to various concentrations of Akt1/2 inhibitor for 72 hours. Cell survival was calculated as the number of cells surviving relative to the number of cells surviving in the control group. (C) Western blot results showing endogenous p-Akt expression levels in RMUG-S and RMUG-L cells after treatment with 15 uM of Akt1/2 inhibitor
Figure S6 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Authors: Liu Tao , Hu Wei , Dalton Heather J. , Choi Hyun Jin , Huang Jie , Kang Yu , Pradeep Sunila , Miyake Takahito , Song Jian H. , Wen Yunfei , Lu Chunhua , Pecot Chad V. , Bottsford-Miller Justin , Zand Behrouz , Jennings Nicholas B. , Ivan Cristina , Gallick Gary E. , Baggerly Keith A. , Hangauer David G. , Coleman Robert L. , Frumovitz Michael , Sood Anil K.
Published: April 2023

PDF file 190K, Figure S6. (A, B) Glu-tubulin immunofluorescence staining (green) in RMUG-S and RMUG-L cells treated with 100 nM KX-01 for 24 hours and incubated with anti-glu-tubulin antibody followed by Alexa Fluor 488-conjugated anti-rabbit antibody. Nuclei (blue) were stained with DAPI. Left: tubulin stain only; Middle: DAPI nuclear stain; Right: tubulin and DAPI nuclear stain
Figure S5 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Authors: Liu Tao , Hu Wei , Dalton Heather J. , Choi Hyun Jin , Huang Jie , Kang Yu , Pradeep Sunila , Miyake Takahito , Song Jian H. , Wen Yunfei , Lu Chunhua , Pecot Chad V. , Bottsford-Miller Justin , Zand Behrouz , Jennings Nicholas B. , Ivan Cristina , Gallick Gary E. , Baggerly Keith A. , Hangauer David G. , Coleman Robert L. , Frumovitz Michael , Sood Anil K.
Published: April 2023

PDF file 218K, Figure S5. (A) 72 proteins significantly differed between cells treated with KX-01 and control cells in RMUG-S cells. (B) 60 proteins significantly differed between cells treated with KX-01 and control cells in RMUG-L cells. (C) Western blot results showing cyclin B1 and CDC2 expression in RMUG-S and RMUG-L cells treated with 100nM or 200nM KX-01 for 24 hours. Bars represent means with standard errors. *p<0.05 compared with the control group. (D, E) Lamin B1 immunofluorescence staining (green) in RMUG-S and RMUG-L cells treated with 100 nM KX-01 for 24 hours and incubated with anti-lamin B1 antibody. Nuclei (blue) were stained with DAPI
Figure S2 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Authors: Liu Tao , Hu Wei , Dalton Heather J. , Choi Hyun Jin , Huang Jie , Kang Yu , Pradeep Sunila , Miyake Takahito , Song Jian H. , Wen Yunfei , Lu Chunhua , Pecot Chad V. , Bottsford-Miller Justin , Zand Behrouz , Jennings Nicholas B. , Ivan Cristina , Gallick Gary E. , Baggerly Keith A. , Hangauer David G. , Coleman Robert L. , Frumovitz Michael , Sood Anil K.
Published: April 2023

PDF file 196K, Figure S2. Effects of KX-01 and oxaliplatin on cell proliferation (Ki-67; A), angiogenesis (CD31; B), apoptosis (Cleaved caspase-3; C) RMUG-L model. Original magnification 200x . Bars in the graphs correspond sequentially to the labeled columns of images on the left. Data are shown as mean {plus-minus} standard deviation (error bars). *p<0.05, **p<0.01 compared with the control group
Figure S1 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Authors: Liu Tao , Hu Wei , Dalton Heather J. , Choi Hyun Jin , Huang Jie , Kang Yu , Pradeep Sunila , Miyake Takahito , Song Jian H. , Wen Yunfei , Lu Chunhua , Pecot Chad V. , Bottsford-Miller Justin , Zand Behrouz , Jennings Nicholas B. , Ivan Cristina , Gallick Gary E. , Baggerly Keith A. , Hangauer David G. , Coleman Robert L. , Frumovitz Michael , Sood Anil K.
Published: April 2023

PDF 116K, Figure S1. (A) Western blot results for p-paxillin and p-P130cas for the dose-finding experiment. HeyA8 cells were injected into the peritoneal cavity of 18 nude mice (2.5x105 cells per mouse). When tumors were palpable (4-5 weeks after the injection), mice were given 1 dose of 15mg/kg or 25mg/kg KX-01 orally. At 24, 36, or 48 hours after the treatment, mice were sacrificed and tumor tissues harvested. (B, C) Mouse weight following treatment in the RMUG-S and RMUG-L models (mean {plus-minus} standard deviation). No significant weight loss was observed in any of the groups
Supplementary Figure Legends from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
Authors: Sidhu Roger , Rong Alan , Dahlberg Steve
Published: April 2023

PDF file - 40 KB
Supplementary Figure 1C from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
Authors: Sidhu Roger , Rong Alan , Dahlberg Steve
Published: April 2023

PDF file - 50 KB, Phase III trials with targeted therapies
Supplementary Fig. 1 from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer
Authors: Kaur Sukhwinder , Sharma Neil , Krishn Shiv Ram , Lakshmanan Imay , Rachagani Satyanarayana , Baine Michael J. , Smith Lynette M. , Lele Subodh M. , Sasson Aaron R. , Guha Sushovan , Mallya Kavita , Anderson Judy M. , Hollingsworth Michael A. , Batra Surinder K.
Published: April 2023

PDF file 89K, Effect of lipocalin 2 on MUC4 expression in pancreatic cancer cell lines
Supplementary Tables 1 - 4, Figures 1 - 2 from Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs
Authors: Jardim Denis L. , Hess Kenneth R. , LoRusso Patricia , Kurzrock Razelle , Hong David S.
Published: April 2023

PDF file - 309K, Supplemental table 1 - Drugs included in the analysis and their respective phase I trials. Supplemental table 2 - Drugs included in the analysis and their respective schedule and later trial leading to FDA approval. Supplemental table 3 - Agents and Phase I trials characteristics. Supplemental table 4 - Univariate analysis of the probability of adopting the RP2D plus or minus 20% according to phase I trials characteristics. Supplemental Figure 1 - Flow diagram of search results. Supplemental figure 2 - Analysis of the probability of adopting the RP2D in relation to continuous variables.
Supplementary Methods from Combined Administration of Rituximab and ON 013105 Induces Apoptosis in Mantle Cell Lymphoma Cells and Reduces Tumor Burden in a Mouse Model of Mantle Cell Lymphoma
Authors: Prasad Anil , Shrivastava Ashutosh , Papadopoulos Evangelos , Kuzontkoski Paula M. , Reddy M.V. Ramana , Gillum Amanda M. , Kumar Ramesh , Reddy E. Premkumar , Groopman Jerome E.
Published: April 2023

PDF file - 100K, Supplementary Methods including: cells, antibodies, preparation of GST-eIF4E and GB1-eIF4E proteins, assessing protein/compound binding by saturation transfer difference (STD) and 1D 1H-NMR spectra, assessing protein/compound binding with protein titration and 1D 1H-NMR spectra, fluorescence intensity quenching, pharmacokinetic analysis and routes of ON 013105 administration.
Supplementary Figure 5 from Tumor Suppressive Effects of Bromodomain-Containing Protein 7 (BRD7) in Epithelial Ovarian Carcinoma
Authors: Park Young-Ae , Lee Jeong-Won , Kim Hye-Sun , Lee Yoo-Young , Kim Tae-Joong , Choi Chel Hun , Choi Jung-Joo , Jeon Hye-Kyung , Cho Young Jae , Ryu Ji Yoon , Kim Byoung-Gie , Bae Duk-Soo
Published: April 2023

PDF - 1244K, BRD7 mediated reduction of MMP2 require beta-catenin pathway. A2780 (A) or SKOV3 (B) cells were co-transfected with BRD7 plasmid and beta-catenin siRNA. After 36 hours, whole mRNA was isolated and cDNA was synthesized. Semi-quantitative PCR was performed to estimate the expression of MMP2 mRNA.
Supplementary Figure 4 from Tumor Suppressive Effects of Bromodomain-Containing Protein 7 (BRD7) in Epithelial Ovarian Carcinoma
Authors: Park Young-Ae , Lee Jeong-Won , Kim Hye-Sun , Lee Yoo-Young , Kim Tae-Joong , Choi Chel Hun , Choi Jung-Joo , Jeon Hye-Kyung , Cho Young Jae , Ryu Ji Yoon , Kim Byoung-Gie , Bae Duk-Soo
Published: April 2023

PDF - 1246K, Western blot analysis was used to determine expression levels of MEK1 and p-ERK (1/2) when two ovarian cancer cells were transfected with BRD7 plasmid.
Supplementary Figure 2 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Authors: Gil del Alcazar Carlos Rodrigo , Hardebeck Molly Catherine , Mukherjee Bipasha , Tomimatsu Nozomi , Gao Xiaohuan , Yan Jingsheng , Xie Xian-Jin , Bachoo Robert , Li Li , Habib Amyn A. , Burma Sandeep
Published: April 2023

PDF file - 650K, NVP-BEZ235 impairs growth of U87-vIII tumors when given in conjunction with IR.
Supplementary Figure 1 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Authors: Gil del Alcazar Carlos Rodrigo , Hardebeck Molly Catherine , Mukherjee Bipasha , Tomimatsu Nozomi , Gao Xiaohuan , Yan Jingsheng , Xie Xian-Jin , Bachoo Robert , Li Li , Habib Amyn A. , Burma Sandeep
Published: April 2023

PDF file - 246K, NVP-BEZ235 inhibits the DDR in U87-vIII cells.
Supplementary Figure Legend from DNA Demethylating Agents Synergize with Oncolytic HSV1 against Malignant Gliomas
Authors: Okemoto Kazuo , Kasai Kazue , Wagner Benjamin , Haseley Amy , Meisen Hans , Bolyard Chelsea , Mo Xiaokui , Wehr Allison , Lehman Amy , Fernandez Soledad , Kaur Balveen , Chiocca E. Antonio
Published: April 2023

PDF file - 96K
Supplementary Figure 4 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Authors: Chini Claudia C.S. , Guerrico Anatilde M. Gonzalez , Nin Veronica , Camacho-Pereira Juliana , Escande Carlos , Barbosa Maria Thereza , Chini Eduardo N.
Published: April 2023

PDF file - 60K, Effect of another CD38 siRNA on cell viability.
Supplementary Figure Legends from A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
Authors: Wagner Andrew J. , Chugh Rashmi , Rosen Lee S. , Morgan Jeffrey A. , George Suzanne , Gordon Michael , Dunbar Joi , Normant Emmanuel , Grayzel David , Demetri George D.
Published: April 2023

Supplementary Figure Legend - PDF file 74K, Supplementary figure legend
Supplementary Figure 2 from A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
Authors: Wagner Andrew J. , Chugh Rashmi , Rosen Lee S. , Morgan Jeffrey A. , George Suzanne , Gordon Michael , Dunbar Joi , Normant Emmanuel , Grayzel David , Demetri George D.
Published: April 2023

Supplementary Figure 2 - PDF file 49K, Example Western Blot Showing that IPI 504 above 150 mg/m2 Induces an Increase in Hsp70 in PBLs from GIST Patients PBLs were purified from GIST patient samples, and lysed. Ten microg of protein lysates were run on an SDS-PAGE minigel. After transfer, the membrane was labeled using anti-Hsp70 antibody and chemiluminescence
Supplementary Tables 1-5 from Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
Authors: McCaffery Ian , Tudor Yanyan , Deng Hongjie , Tang Rui , Suzuki Samuel , Badola Sunita , Kindler Hedy L. , Fuchs Charles S. , Loh Elwyn , Patterson Scott D. , Chen Li , Gansert Jennifer L.
Published: April 2023

Supplementary Table S1 (Multivariate analysis for circulating biomarkers.) Supplementary Table S2 (Summary of KRAS mutational status in the ganitumab arm.) Supplementary Table S3 (Association of KRAS mutational status with OS in the ganitumab arm.) Supplementary Table S4 (Summary of PTEN expression in the ganitumab arm.) Supplementary Table S5 (Association of PTEN expression with OS in the ganitumab arm.)
Supplementary Figure 2 from PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Authors: Erdreich-Epstein Anat , Robison Nathan , Ren Xiuhai , Zhou Hong , Xu Jingying , Davidson Tom B. , Schur Mathew , Gilles Floyd H. , Ji Lingyun , Malvar Jemily , Shackleford Gregory M. , Margol Ashley S. , Krieger Mark D. , Judkins Alexander R. , Jones David T.W. , Pfister Stefan M. , Kool Marcel , Sposto Richard , Asgharazadeh Shahab
Published: April 2023

PDF file - 190K, Supplemental Fig 2: Proneural and Neural GBMs have higher PID1 mRNA; higher PID1 mRNA correlates with higher OS in patients with gliomas.
Supplementary Figure 6 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
Authors: de Haart Sanne J. , van de Donk Niels W.C.J. , Minnema Monique C. , Huang Julie H. , Aarts-Riemens Tineke , Bovenschen Niels , Yuan Huipin , Groen Richard W.J. , McMillin Douglas W. , Jakubikova Jana , Lokhorst Henk M. , Martens Anton C. , Mitsiades Constantine S. , Mutis Tuna
Published: April 2023

Supplementary Figure 6 - PDF file 74K, Synergistic interaction of YM155 and CTLs. In A, the effect of YM155 on survivin and MCL-1 protein levels of MM cells is shown. The cells were cultured with YM155 during 24h and the western blot assays were carried out as indicated in material methods. Band intensities were quantified using image J software, calculated as relative values to the control protein tubuline and plotted as relative to the expression levels of cells cultured without YM155. In B, the type of interaction between YM155 and CTLs (see figure 5C-D) in the presence of accessory cells was analyzed using Compusyn software (version 1.0, 2004 �). In the plots (A) the CI values corresponding to the doses in figure 5 are shown. A CI value of <1, 1 or >1 indicates synergy, additive effects or antagonism, respectively. In C the supernatants of assays as described in Fig 5C-D granzyme B release was measured using ELISA (B). Results are expressed as the mean values of the triplicate cultures. Error bars represent the SEM. Results are representative of 3 independent assays
Supplementary Table 3 from Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
Authors: Pardini Barbara , Rosa Fabio , Barone Elisa , Di Gaetano Cornelia , Slyskova Jana , Novotny Jan , Levy Miroslav , Garritano Sonia , Vodickova Ludmila , Buchler Tomas , Gemignani Federica , Landi Stefano , Vodicka Pavel , Naccarati Alessio
Published: April 2023

PDF file - 86K, SNPs associated with EFS in the Training set (Cox regression for adjusted estimates).
Supplementary Table 2 from Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
Authors: Pardini Barbara , Rosa Fabio , Barone Elisa , Di Gaetano Cornelia , Slyskova Jana , Novotny Jan , Levy Miroslav , Garritano Sonia , Vodickova Ludmila , Buchler Tomas , Gemignani Federica , Landi Stefano , Vodicka Pavel , Naccarati Alessio
Published: April 2023

PDF file - 88K, Overall and event-free survival in relation to SNP distributions in the Training set (Cox regression for adjusted estimates).
Supplementary Materials and Methods from HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer
Authors: Sehdev Vikas , Katsha Ahmed , Arras Janet , Peng Dunfa , Soutto Mohammed , Ecsedy Jeffrey , Zaika Alexander , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supplementary Materials and Methods PDF file 37K, Supplementary Materials and Methods
Supplementary Figure 5 from HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer
Authors: Sehdev Vikas , Katsha Ahmed , Arras Janet , Peng Dunfa , Soutto Mohammed , Ecsedy Jeffrey , Zaika Alexander , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

PDF file 1254K, AURKA is present in an immunocomplex with HDM2
Supplementary Figures from Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets
Authors: Van Laere Steven J. , Ueno Naoto T. , Finetti Pascal , Vermeulen Peter , Lucci Anthony , Robertson Fredika M. , Marsan Melike , Iwamoto Takayuki , Krishnamurthy Savitri , Masuda Hiroko , van Dam Peter , Woodward Wendy A. , Viens Patrice , Cristofanilli Massimo , Birnbaum Daniel , Dirix Luc , Reuben James M. , Bertucci François
Published: April 2023

Supplementary Figures PDF file - 529K, Supplementary Figure 1: Application of the Gaussian mixture model to ESR1- and ERBB2-expression data Supplementary Figure 2: Normalization Supplementary Figure 3: Silhouette Analysis Supplementary Figure 4: Silhouette Analysis (P-Values) Supplementary Figure 5: Validation of Limma-corrected IBC/nIBC signature Supplementary Figure 6: Networks overrepresented in IBC Supplementary Figure 7: Networks overrepresented in nIBC Supplementary Figure 8: Prognostic value of the IBC/nIBC signature in nIBC
Supplementary Table 1 from A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
Authors: Ross Jeffrey S. , Wang Kai , Gay Laurie M. , Al-Rohil Rami N. , Nazeer Tipu , Sheehan Christine E. , Jennings Timothy A. , Otto Geoff A. , Donahue Amy , He Jie , Palmer Gary , Ali Siraj , Nahas Michelle , Young Geneva , LaBrecque Elaine , Frampton Garrett , Erlich Rachel , Curran John A. , Brennan Kristina , Downing Sean R. , Yelensky Roman , Lipson Doron , Hawryluk Matthew , Miller Vincent A. , Stephens Philip J.
Published: April 2023

PDF file - 207K, Supplementary Table Genomic Alterations in 64 Cases of Relapsed/Metastatic Non-Micropapillary Urothelial Carcinoma of the Bladder.
Supplementary Figure 5 from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 60K, Supplemental Figure 5. Effect of CX-4945 on Survival of GBM Xenograft Cells.
Supplementary Table 4 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
Authors: Kandimalla Raju , Masius Roy , Beukers Willemien , Bangma Chris H. , Orntoft Torben F. , Dyrskjot Lars , van Leeuwen Nikki , Lingsma Hester , van Tilborg Angela A.G. , Zwarthoff Ellen C.
Published: April 2023

PDF file, 37K, Spearmen correlation among three methylation markers as well as among methylation assay, cytology and FGFR3 assay.
Supplementary Figure Legends from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
Authors: Kandimalla Raju , Masius Roy , Beukers Willemien , Bangma Chris H. , Orntoft Torben F. , Dyrskjot Lars , van Leeuwen Nikki , Lingsma Hester , van Tilborg Angela A.G. , Zwarthoff Ellen C.
Published: April 2023

PDF file, 89K.
Supplementary Figure 6 from Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
Authors: Cosimo Emilio , McCaig Alison M. , Carter-Brzezinski Luke J.M. , Wheadon Helen , Leach Michael T. , Le Ster Karine , Berthou Christian , Durieu Emilie , Oumata Nassima , Galons Hervé , Meijer Laurent , Michie Alison M.
Published: April 2023

PDF file - 49K, Co-culture of CLL cells with CD154L/IL4 increases RelA activity.
Supplementary Table 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Authors: Zaid Tarrik M. , Yeung Tsz-Lun , Thompson Melissa S. , Leung Cecilia S. , Harding Tom , Co Ngai-Na , Schmandt Rosie S. , Kwan Suet-Ying , Rodriguez-Aguay Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Wong Kwong-Kwok , Birrer Michael J. , Mok Samuel C.
Published: April 2023

PDF file - 2007K, Results of Biacore studies of FGFR4mut:Fc FGF-binding affinity
Supplementary Figure 5 from Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
Authors: Cosimo Emilio , McCaig Alison M. , Carter-Brzezinski Luke J.M. , Wheadon Helen , Leach Michael T. , Le Ster Karine , Berthou Christian , Durieu Emilie , Oumata Nassima , Galons Hervé , Meijer Laurent , Michie Alison M.
Published: April 2023

PDF file - 96K, CR8 induces CLL cell apoptosis in a caspase-dependent manner.
Supplementary Figure 6 from Identification of miR-133b and RB1CC1 as Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer
Authors: Li Xia , Wan Xuechao , Chen Hongbing , Yang Shu , Liu Yiyang , Mo Wenjuan , Meng Delong , Du Wenting , Huang Yan , Wu Hai , Wang Jingqiang , Li Tao , Li Yao
Published: April 2023

PDF file - 229KB, RB1CC1 affected cell cycle and apoptosis in LNCaP cells.
Supplementary Figure 5 from Identification of miR-133b and RB1CC1 as Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer
Authors: Li Xia , Wan Xuechao , Chen Hongbing , Yang Shu , Liu Yiyang , Mo Wenjuan , Meng Delong , Du Wenting , Huang Yan , Wu Hai , Wang Jingqiang , Li Tao , Li Yao
Published: April 2023

PDF file - 234KB, Identifying putative targets of miR-133b.
Supplementary Figure 4 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair
Authors: Wei Dongping , Parsels Leslie A. , Karnak David , Davis Mary A. , Parsels Joshua D. , Marsh Amanda C. , Zhao Lili , Maybaum Jonathan , Lawrence Theodore S. , Sun Yi , Morgan Meredith A.
Published: April 2023

PDF file - 63K, LB100 produces minimal radiosensitization in normal cells.
Supplementary Figure 4 from Identification of miR-133b and RB1CC1 as Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer
Authors: Li Xia , Wan Xuechao , Chen Hongbing , Yang Shu , Liu Yiyang , Mo Wenjuan , Meng Delong , Du Wenting , Huang Yan , Wu Hai , Wang Jingqiang , Li Tao , Li Yao
Published: April 2023

PDF file - 458KB, Quantitative analyses of activated caspase and caspase-3 in LNCaP and PC-3 cells and the transfection efficiency in these two cell lines.
Supplementary Figure 2 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair
Authors: Wei Dongping , Parsels Leslie A. , Karnak David , Davis Mary A. , Parsels Joshua D. , Marsh Amanda C. , Zhao Lili , Maybaum Jonathan , Lawrence Theodore S. , Sun Yi , Morgan Meredith A.
Published: April 2023

PDF file - 77K, PPP2R1A depletion causes an increase in pHistone H3 (Ser10) positive cells.
Supplementary Figure 2 from Identification of miR-133b and RB1CC1 as Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer
Authors: Li Xia , Wan Xuechao , Chen Hongbing , Yang Shu , Liu Yiyang , Mo Wenjuan , Meng Delong , Du Wenting , Huang Yan , Wu Hai , Wang Jingqiang , Li Tao , Li Yao
Published: April 2023

PDF file - 240KB, Quantitative analyses of cell cycle in LNCaP and PC-3 cells and the transfection efficiency of cell cycle assays in these two cell lines.
Supplementary Methods and Figure Legend from A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
Authors: Reardon David A. , Groves Morris D. , Wen Patrick Y. , Nabors Louis , Mikkelsen Tom , Rosenfeld Steve , Raizer Jeffrey , Barriuso Jorge , McLendon Roger E. , Suttle A. Benjamin , Ma Bo , Curtis C. Martin , Dar Mohammed M. , de Bono Johann
Published: April 2023

PDF file - 82K
Supplementary Figure 1 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features
Authors: Morabito Fortunato , Mosca Laura , Cutrona Giovanna , Agnelli Luca , Tuana Giacomo , Ferracin Manuela , Zagatti Barbara , Lionetti Marta , Fabris Sonia , Maura Francesco , Matis Serena , Gentile Massimo , Vigna Ernesto , Colombo Monica , Massucco Carlotta , Recchia Anna Grazia , Bossio Sabrina , De Stefano Laura , Ilariucci Fiorella , Musolino Caterina , Molica Stefano , Di Raimondo Francesco , Cortelezzi Agostino , Tassone Pierfrancesco , Negrini Massimo , Monti Sara , Rossi Davide , Gaidano Gianluca , Ferrarini Manlio , Neri Antonino
Published: April 2023

PDF file - 22K, Distribution of the most frequently utilized IGHV. The histogram shows the percentages of VH sequences used in cMBL compared to Rai0-CLL cases.
Supplementary Table S3 from The Tumor-Suppressive Function of UNC5D and Its Repressed Expression in Renal Cell Carcinoma
Authors: Lu Dan , Dong Dong , Zhou Yu , Lu Min , Pang Xue-Wen , Li Yan , Tian Xiao-Jun , Zhang Yu , Zhang Jun
Published: April 2023

Supplementary Table S3 - PDF file 62K, Supplementary Table S3. Correlation of UNC5D expression with methylation and LOH status in primary tumors
Supplementary Table 3 from Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Authors: Horak Christine E. , Pusztai Lajos , Xing Guan , Trifan Ovidiu C. , Saura Cristina , Tseng Ling-Ming , Chan Stephen , Welcher Rosanne , Liu David
Published: April 2023

PDF file - 78K, Logistic regression: βIII-tubulin, other β-tubulin isoforms, TACC3 and CAPG (randomized patients with non-missing pCR and biomarker expressions)
Supplementary Figure 5 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Authors: Floris Giuseppe , Wozniak Agnieszka , Sciot Raf , Li Haifu , Friedman Lori , Van Looy Thomas , Wellens Jasmien , Vermaelen Peter , Deroose Christophe M. , Fletcher Jonathan A. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

PDF file - 4757K, Western blotting showing KIT oncogenic signaling cascade. Three different tumor lysates were analyzed per treatment group.
Supplementary Figure 1 from Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins
Authors: Travica Sandra , Pors Klaus , Loadman Paul M. , Shnyder Steven D. , Johansson Inger , Alandas Mohammed N. , Sheldrake Helen M. , Mkrtchian Souren , Patterson Laurence H. , Ingelman-Sundberg Magnus
Published: April 2023

Supplementary Figure 1 - PDF file 89K, Structures of the compounds used in the study
Supplementary Figures 1 - 2, Table 1 from Antitumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells
Authors: Lim Junghee , Duong Tam , Do Nga , Do Phuong , Kim Jaetaek , Kim Hyuncheol , El-Rifai Wael , Ruley H. Earl , Jo Daewoong
Published: April 2023

PDF file - 348K, Supplementary Figure S1. Selected MTDs promote efficient cellular uptake of MTD-containing proteins by cultured cells and enhance the systemic delivery to tissues. Supplementary Figure S2. Body weights of tumor bearing mice. Supplementary Table S1. Summary of MTDs.
Supplementary Figure 5 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification
Authors: Zheng Jianghua , Wang Jinglong , Sun Xueqing , Hao Mingang , Ding Tao , Xiong Dan , Wang Xiumin , Zhu Yu , Xiao Gang , Cheng Guangcun , Zhao Meizhong , Zhang Jian , Wang Jianhua
Published: April 2023

PDF file - 247K, CXCR7 expression regulated by HIC1 in PCa cells
Supplementary Table 2 from A Molecular Taxonomy for Urothelial Carcinoma
Authors: Sjödahl Gottfrid , Lauss Martin , Lövgren Kristina , Chebil Gunilla , Gudjonsson Sigurdur , Veerla Srinivas , Patschan Oliver , Aine Mattias , Fernö Mårten , Ringnér Markus , Månsson Wiking , Liedberg Fredrik , Lindgren David , Höglund Mattias
Published: April 2023

XLS file - 22K, Summary of patient and sample data